[1]
Darnell, J.E. Transcription factors as targets for cancer therapy. J. Nat. Rev. Cancer, 2002, 2, 740.
[2]
Kibria, G.; Hatakeyama, H.; Harashima, H. Cancer multidrug resistance: Mechanisms involved and strategies for circumvention using a drug delivery system. Arch. Pharm. Res., 2014, 37, 4.
[3]
Gibbs, J.B. Mechanism-based target identification and drug discovery in cancer research. Science, 2000, 287, 1969.
[4]
Reed, J.C.; Tomaselli, K.J. Drug discovery opportunities from apoptosis research. Curr. Opin. Biotechno., 2000, 11, 586.
[5]
Fischer, U.; Schulze-Osthoff, K. Apoptosis-based therapies and drug targets. Cell Death Differ., 2005, 942.
[6]
Mollinedo, F.; Gajate, C. Microtubules, microtubule-interfering agents and apoptosis., 2003, 8, 413.
[7]
Simoni, D.; Tolomeo, M. Retinoids, apoptosis and cancer. Curr. Pharm. Des., 2001, 7, 1823.
[8]
Fesik, S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer, 2005, 5, 876.
[9]
Zhang, H.Z.; Kasibhatla, S.; Kuemmerle, J.; Kemnitzer, W.; Ollis-Mason, K.; Qiu, L.; Crogan-Grundy, C.; Tseng, B.; Drewe, J.; Cai, S.X. Discovery and structure-activity relationship of 3-aryl-5-aryl-1, 2, 4-oxadiazoles as a new series of apoptosis inducers and potential anticancer agents. J. Med. Chem., 2005, 48, 5215.
[10]
Porretta, G.C.; Cerreto, F.; Fioravanti, R.; Scalzo, M.; Fischetti, M.; Riccardi, F.; de-Joannon, C.A.; de-Feo, G.; Mazzanti, G.; Tolu, L. Green Route to the 2,6-Disubstituted Imidazo[2,1-b]-1,3,4-Thiadiazoles by the cyclocondensation of α-bromoacetophenone derivative and 1,3,4- Thiadiazoles using ionic liquids. Farmaco, Sci., 1988, 43, 15.
[11]
Zuliani, V.; Fantini, M.; Nigam, A.; Stables, J.P.; Patel, M.K.; Rivara, M. Anticonvulsant activity of 2,4(1H)-diarylimidazoles in mice and rats acute seizure models. Bioorg. Med. Chem., 2010, 18, 7957.
[12]
Fantini, M.; Rivara, M.; Zuliani, V.; Kalmar, C.L.; Vacondio, F.; Silva, C.; Baheti, A.R.; Singh, N.; Merrick, E.C.; Katari, R.S.; Cocconcelli, G.; Ghiron, C.; Patel, M.K. 2,4(5)-Diarylimidazoles as inhibitors of hNaV1.2 sodium channels: Pharmacological evaluation and structure-property relationships. Bioorg. Med. Chem., 2009, 17, 3642.
[13]
(a) Tuyen, T.N.; Sin, K.S.; Kim, H.P.; Park, H. Synthesis and antiinflammatory activity of 1,5-Diarylimidazoles. Arch. Pharmacol. Res., 2005, 28, 1013.
(b) Khanna, I.K.; Yu, Y.; Huff, R.M.; Weier, R.M.; Xu, X.; Koszyk, F.J.; Collins, P.W.; Cogburn, J.N.; Isakson, P.C.; Koboldt, C.M.; Masferrer, J.L.; Perkins, W.E.; Seibert, K.; Veenhuizen, A.W.; Yuan, J.; Yang, D.C.; Zhang, Y.Y. Selective cyclooxygenase-2 Inhibitors: Heteroaryl modified 1,2-Diarylimidazoles are potent, orally activeanti-inflammatory agents. J. Med. Chem., 2000, 43, 3168.
[14]
Plummer, C.W.; Finke, P.E.; Mills, S.G.; Wang, J.; Tong, X.; Doss, G.A.; Fong, T.M.; Lao, J.Z.; Schaeffer, M.T.; Chen, J.; Shen, C.P.; Stribling, D.S.; Shearman, L.P.; Strack, A.M.; Van-der-Ploeg, L.H. Design, synthesis and in vitro antimicrobial evaluation of novel Imidazo[1,2-a]pyridine and imidazo[2,1-b][1,3]benzothiazole motifs. Bioorg. Med. Chem. Lett., 2005, 15, 1441.
[15]
Bellina, F.; Cauteruccio, S.; Di-Fiore, A.; Rossi, R. Regioselective synthesis of 4,5-Diaryl-1-methyl-1H-imidazoles including highly cytotoxic derivatives by Pd-catalyzed direct C-5 arylation of 1-Methyl-1H-imidazole with aryl bromides. Eur. J. Org. Chem., 2008, 32, 5436.
[16]
Bonezzi, K.; Taraboletti, G.; Borsotti, P.; Bellina, F.; Rossi, R.; Giavazzi, R. Vascular disrupting activity of tubulin-binding 1,5-Diaryl-1H-imidazoles. J. Med. Chem., 2009, 52, 7906.
[17]
(a) Schobert, R.; Biersack, B.; Dietrich, A.; Effenberger, K.; Knauer, S.; Mueller, T. 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin a resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model. J. Med. Chem., 2010, 53, 6595.
(b) Li, W.T.; Hwang, D.R.; Song, J.S.; Chen, C.P.; Chuu, J.J.; Hu, C.B.; Lin, H.L.; Huang, C.L.; Huang, C.Y.; Tseng, H.Y.; Lin, C.C.; Chen, T.W.; Lin, C.H.; Wang, H.S.; Shen, C.C.; Chang, C.M.; Chao, Y.S.; Chen, C.T. Synthesis and biological activities of 2-amino-1-arylidenamino imidazoles as orally active anticancer agents. J. Med. Chem., 2010, 53, 2409.
[18]
(a)Cremlyn, R.J. An Introduction to Organosulfur Chemistry; John Wiley & Sons: Chichester, 1996.
(b) Hulten, J.; Bonham, N.M.; Nillroth, U.; Hansson, T.; Zuccarello, G.; Bouzide, A.; Aaqvist, J.; Classon, B.; Danielson, H. Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities. J. Med. Chem., 1997, 40, 885.
(c) Dauben, P.; Dodd, R.H. Synthesis of Cyclic sulfonamides via intramolecular copper-catalyzed reaction of unsaturated iminoiodinanes. Org. Lett., 2000, 2, 2327.
(d) Katritzky, A.R.; Wu, J.; Rachwal, S.; Rachwal, B.; Macomber, D.W.; Smith, T.P. Preparation of 6-, 7- and 8-membered sultams by friedel-crafts cyclization of ω-phenylalkanesulfamoyl chlorides. Org Prep Proced, 1992, 24, 463.
(e) Greig, I.R.; Tozer, M.J.; Wright, P.T. Synthesis of cyclic sulfonamides through intramolecular diels−alder reactions. Org. Lett., 2001, 3, 369.
(f) Matthew, D.M.; Joseph, M.D.; Paul, R.H. Synthesis of phosphorus and sulfur heterocycles via ring-closing olefin metathesis. Chem. Rev., 2004, 104, 2239-2258.
(g) Dawson, P.E.; Muir, T.W.; Lewis, C.I.; Kent, S.B.H. Synthesis of proteins by native chemical ligation. Science, 1994, 266, 776.
[19]
(a) Farag, A.M.; Mayhoub, A.S.; Barakat, S.E.; Bayomi, A.H. Synthesis of new N-phenylpyrazole derivatives with potent antimicrobial activity. Bioorg. Med. Chem., 2008, 16, 4569-4578.
(b) Al-Tel, T.H.; Al-Qawasmeh, R.A.; Zaarour, R. Design, synthesis and in vitro antimicrobial evaluation of novel Imidazo[1,2-a]pyridine and imidazo[2,1-b][1,3]benzothiazole motifs. Eur. J. Med. Chem., 2011, 46, 1874-1881.
[20]
(a) Furlan, A.; Colombo, F.; Kover, A.; Issaly, N. Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signalling. Eur. J. Med. Chem., 2012, 47, 239.
(b) Andreani, A.; Burnelli, S.; Granaiola, M.; Leoni, A. New Antitumor Imidazo[2,1-b]thiazole Guanylhydrazones and Analogues. J. Med. Chem., 2008, 51, 809.
(c) Andreani, A.; Granaiola, M.; Locatelli, A.; Morigi, R. Substituted 3-(5-Imidazo[2,1-b]thiazolylmethylene)-2-indolinones and Analogues: Synthesis, Cytotoxic Activity, and Study of the Mechanism of Action. J. Med. Chem., 2012, 55, 2078.
(d) Andreani, A.; Burnelli, S.; Granaiola, M.; Leoni, A. Antitumor Activity of New Substituted 3-(5-Imidazo[2,1-b]thiazolylmethylene)-2-indolinones and 3-(5-Imidazo[2,1-b]thiadiazolylmethylene)-2-indolinones: Selectivity against Colon Tumor Cells and Effect on Cell Cycle-Related Events. J. Med. Chem., 2008, 51, 7508.
(e) Trapani, G.; Franco, M.; Latrofa, A.; Reho, A.; Liso, G. Synthesis, in vitro and in vivo cytotoxicity, and prediction of the intestinal absorption of substituted 2-ethoxycarbonyl-imidazo[2,1-b]benzothiazoles. Eur. J. Pharm. Sci., 2001, 14, 209.
[21]
Ager, I.R.; Barnes, A.C.; Danswan, G.W.; Hairsine, P.W. Synthesis and oral antiallergic activity of carboxylic acids derived from imidazo[2,1-c][1,4]benzoxazines, imidazo[1,2-a]quinolines, imidazo [1,2-a]quinoxalines, imidazo[1,2-a]quinoxalinones, pyrrolo[1,2-a]quinoxalinones, pyrrolo[2,3-a]quinoxalinones, and imidazo[2,1-b]benzothiazoles. J. Med. Chem., 1988, 31, 1098.
[22]
Palkar, M.; Noolvi, M.; Sankangoud, R.; Maddi, V. Synthesis and antibacterial activity of a novel series of 2,3-diaryl-substituted-imidazo(2,1-b)-benzothiazole derivatives. Arch. Pharm. Chem. Life Sci, 2010, 343, 353.
[23]
Chao, Q.; Sprankle, K.G.; Grotzfeld, R.M.; Lai, A.G.; Carter, T.A.; Velasco, A.M.; Gunawardane, R.N.; Cramer, M.D.; Gardner, M.F.; James, J.; Zarrinkar, P.P.; Patel, H.K.; Bhagwat, S.S. Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N′-4-[7-(2-morpholin-4-yl-ethoxy) imidazo[2,1 b][1,3]benzothiazol-2-yl]phenylurea Dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-Like Tyrosine Kinase-3 (FLT3) inhibitor. J. Med. Chem., 2009, 52, 7808.
[24]
Christodoulou, M.S.; Colombo, F.; Passarella, D.; Ieronimo, G.; Zuco, V.; De-Cesare, M.; Zunino, F. Synthesis and biological evaluation of imidazolo[2,1-b] benzothiazole derivatives, as potential p53 inhibitors. Bioorg. Med. Chem., 2011, 19, 1649-1657.
[25]
(a) Kamal, A.; Sultana, F. JanakiRamaiah, M.; Srikanth, Y.V.V.; Viswanath, A.; Kishore, C.; Sharma, P.; Pushpavalli, S.N.C.V.L.; Addlagatta, A.; Bhadra, M.P. 3-Diarylethyne quinazolinones: A new class of senescene inducers. ChemMedChem, 2012, 7, 292.
(b) Shaik, S.P.; Vishnuvardhan, M.V.P.S.; Sultana, F.; Rao, A.V.S.; Bagul, C.; Bhattacharjee, D.; Kapure, J.S.; Jain, N.; Kamal, A. Design and synthesis of 1,2,3-triazolo linked benzo[d]imidazo[2,1-b]thiazole conjugates as tubulin polymerization inhibitors. Bioorg. Med. Chem., 2017, 25, 3285.
(c) Sultana, F.; Reddy, S.B.; Reddy, G.V.; Naik, V.L.; Ravikumar, A.; Rani, S.R.; Alarafi, A.M.; Kumar, S.H.; Kamal, A. Synthesis of benzo[d]imidazo[2,1-b]thiazole-chalcone conjugates as microtubule targeting and apoptosis inducing agents. Bioorg. Chem., 2018, 76, 1-12.
[26]
Amino, N.; Ideyama, Y.; Yamano, M.; Kuromitsu, S.; Tajinda, K.; Samizu, K.; Matsuhisa, A.; Kudoh, M.; Shibasaki, M. YM-201627: An orally active antitumor agent with selective inhibition of vascular endothelial cell proliferation. Cancer Lett., 2006, 238, 119-127.
[27]
Kumbhare, R.M.; Kumar, K.V.; Ramaiah, M.J.; Dadmal, T.; Pushpavalli, S.N.C.V.L.; Mukhopadhyay, D.; Divya, B.; Devi, A.T.; Kosurkar, U.; Pal-Bhadra, M. Synthesis and biological evaluation of novel Mannich bases of 2-arylimidazo[2,1-b]benzothiazoles as potential anti-cancer agents. Eur. J. Med. Chem., 2011, 46, 4258-4266.
[28]
Shaik, S.P.; Nayak, V.L.; Sultana, F.; Rao, A.V.S.; Shaik, A.B.; Babu, K.S.; Kamal, A. Design and synthesis of imidazo[2,1-b]thiazole linked triazole conjugates: Microtubule-destabilizing agents. Eur. J. Med. Chem., 2017, 126, 36-51.
[29]
(a) Reddy, R.M.V.; Akula, B.; Cosenza, S.C.; Lee, C.M.; Mallireddigari, M.R.; Pallela, V.R.; Subbaiah, D.R.C.V.; Udofa, A.; Reddy, E.P. (Z)-1-Aryl-3-arylamino-2-propen-1-ones, highly active stimulators of tubulin polymerization: synthesis, Structure-Activity Relationship (SAR), tubulin polymerization, and cell growth inhibition studies. J. Med. Chem., 2012, 55, 5174-5187.
(b) Zhu, C.; Zuo, Y.; Wang, R.; Liang, B.; Yue, X.; Wen, G.; Shang, N.; Huang, L.; Chen, Y.; Du, J.; Bu, X. Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence. J. Med. Chem., 2014, 57, 6364.
[30]
Botta, M.; Armaroli, S.; Castagnolo, D.; Fontana, G.; Perad, P.; Bombardelli, E. Synthesis and biological evaluation of new taxoids derived from 2-deacetoxytaxinine J. Bioorg. Med. Chem. Lett., 2007, 17, 1579-1583.
[31]
Rodriguez, L.G.; Wu, X.; Guan, J.L. Wound-healing assay. Methods Mol. Biol., 2005, 294, 23.
[32]
Clainche, C.L.; Carlier, M.F. Regulation of actin assembly associated with protrusion and adhesion in cell migration. Physiol. Rev., 2008, 88, 489-513.
[33]
Zhao, Y.; Liu, W.; Zhou, Y.; Zhang, X.; Murphy, P.V.N. -(8-(3-Ethynylphenoxy)octyl-deoxynojirimycin suppresses growth and migration of human lung cancer cells. Bioorg. Med. Chem. Let., 2010, 20, 7540-7543.
[34]
Ly, J.D.; Grubb, D.R.; Lawen, A. The mitochondrial membrane potential (deltapsi(m)) in apoptosis: An update. Apoptosis, 2003, 8, 115-128.
[35]
Emaus, R.K.; Grunwald, R.; Lemasters, J.J. Rhodamine 123 as a probe of transmembrane potential in isolated rat-liver mitochondria: spectral and metabolic properties. Biochim. Biophys. Acta, 1986, 850, 436-448.
[36]
Trachootham, D.; Alexandre, J.; Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov., 2009, 8, 579.
[37]
Lebel, C.P.; Ischiropoulos, H.; Bondy, S.C. Evaluation of the probe 2′,7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem. Res. Toxicol., 1992, 5, 227-231.